Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.63 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.63 |
| ▸ | HTR2B | P41595 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 7/20 | 0.57 |
| ▸ | HTR1D | P28221 | 5/20 | 0.57 |
| ▸ | HTR1A | P08908 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7850885 | 0.88 | HTR2A (0.63) | CYP1A2NFKB1MEN1KMT2AMTNR1A | |
| Hydrochloric Acid SCHEMBL7683721 | 0.86 | NPSR1 (0.64) | CYP1A2NFKB1MEN1KMT2AMTNR1A | |
| SCHEMBL17211933 | 0.86 | HTR2A (0.51) | CYP1A2NFKB1MEN1KMT2AMTNR1A | |
| SCHEMBL2534666 | 0.84 | HTR1A (0.72) | CYP1A2NFKB1MEN1KMT2AMTNR1A | |
| SCHEMBL30022336 | 0.82 | HTR2A (0.65) | CYP1A2NFKB1KMT2AHTR2BCYP3A4 | |
| SCHEMBL7843782 | 0.82 | HTR2A (0.65) | CYP1A2NFKB1KMT2AHTR2BCYP3A4 | |
| SCHEMBL31236315 | 0.82 | HTR2A (0.57) | CYP1A2NFKB1MEN1KMT2AMTNR1A | |
| SCHEMBL12067610 | 0.82 | CYP1A2 (0.64) | CYP1A2NFKB1MEN1KMT2AMTNR1A | |
| Hydrochloric Acid SCHEMBL7681061 | 0.81 | HTR2A (0.63) | CYP1A2NFKB1MEN1KMT2AHTR2B | |
| SCHEMBL28831089 | 0.81 | HTR2A (0.58) | CYP1A2NFKB1MEN1KMT2AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1859798-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2015-12-30 | — | — | EP | disclosed |
| US-8044090-B2 | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2009-12-10 | — | — | US | disclosed |
| EP-1859798-A1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1379239-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2007-05-03 | — | — | US | disclosed |
| US-7157488-B2 | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| CN-1610547-A | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | LILLY CO ELI (US) | 2005-04-27 | — | — | CN | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| EP-0527687-B1 | Novel arylethylamin derivatives, processes for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1995-11-22 | — | — | EP | disclosed |
| US-5380750-A | Arylethylamine compounds | ADIR ET COMPAGNIE (FR) | 1995-01-10 | — | — | US | disclosed |
| US-5308866-A | Treatment of melatonin related disorders, sleep disorders, psychological disorders | ADIR ET COMPAGNIE (FR) | 1994-05-03 | — | — | US | disclosed |
| US-5276051-A | Treatment of melatoninergic system, antiischemic agents and skin disorders using aminoalkylindole compounds | ADIR ET COMPAGNIE (FR) | 1994-01-04 | — | — | US | disclosed |
| EP-0527687-A2 | Novel arylethylamin derivatives, processes for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1993-02-17 | — | — | EP | disclosed |
| US-4087444-A | Amides as ovulation inhibitors | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | CYP1A2 530/4885NFKB1 3646/4885MEN1 1889/4885 |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | CYP1A2 530/4885NFKB1 3646/4885MEN1 1889/4885 |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | CYP1A2 530/4885NFKB1 3646/4885MEN1 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.